Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); it does not constitute any investment advice.
On June 5, 2025, Argo Biopharma announced its hypertension treatment drugBW-00163 has entered Phase II clinical trials.. This drug is an important part of the exclusive licensing cooperation agreement between the company and Novartis.
In January 2024, Argo Biopharma entered into two exclusive licensing and collaboration agreements with Novartis, receiving an upfront payment of $185 million, with a potential total transaction value exceeding $4 billion.As the asset moves into Phase II clinical development,Argo Biopharma Receives Milestone Payment, which will provide important financial support for the company's continuous innovation.ArgoArgo Biopharma owns the next-generation siRNA platform RADS, and BW-00163 is the fourth drug developed on this platform to enter mid-stage clinical trials.Argo Biopharma is a clinical-stage biotechnology company dedicated to developing the next generation of RNAi therapies.Currently, Argo has six RNAi candidate drugs in clinical development, covering multiple therapeutic areas including cardiovascular and cerebrovascular diseases, viral infections, metabolic diseases, and rare diseases.On June 3, 2025, Argo Biopharma's hepatitis B siRNA therapy BW-20507 injection is proposed to be included in the breakthrough treatment drug program. At the annual meeting of the European Association for the Study of the Liver (EASL) held in May 2025, Argo Biopharma announced the Phase I/IIa clinical study data of BW-20507 in treating chronic hepatitis B. The key research data released at the EASL annual meeting showed:- BW-20507 Subcutaneous injection, once every four weeks for a total of three doses, significantly reduced HBsAg levels in a dose-dependent manner, with the maximum reduction observed in the 200 mg and 400 mg dose groups being 2.9~3.2 log₁₀ IU/mL.
- In subjects with baseline HBsAg levels below 1,000 IU/mL, 56% (5/9 cases) achieved HBsAg clearance during the study period.
- Strong HBV DNA suppression was also observed in treatment-naïve subjects not concurrently receiving nucleoside therapy.
In April this year, Argo registered a Phase 2b clinical trial of BW-20507 monotherapy for the treatment of chronic hepatitis B on the Drug Clinical Trial Registration and Information Disclosure Platform. BW-20507 is administered once every four weeks for a total of 13 doses, meaning the treatment cycle lasts one year. According to a press release on Argo's official website, a Phase IIb study of combination therapy for chronic hepatitis B is expected to commence in the third quarter of this year, aiming to further evaluate the potential of BW-20507 in achieving functional cure of chronic hepatitis B.Company Pipeline
Source of the article:Argo Biopharma
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)